EUCTR2009-017995-26-PT进行中（未招募）1 期
PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GELARC
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.)
- •May also be included : de Novo Transformed DLBCL from low grade lymphoma (Follicular, other...) and DLBCL associated with some small cell infiltration in bone marrow
- •-Or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma
- •-Or CD20+ Follicular lymphoma grade 3B
- •-Or CD20+ Agressive B-cell lymphoma unclassifiable
- •?Aged over 80 years.
- •?Ann Arbor stage I, II, III or IV.
- •?Patient non previously treated.
- •?All ECOG performance status
- •?With a minimum life expectancy of 3 months.
- •?Negative HIV, HBV and HCV serologies test = 4 weeks (except after vaccination).
- •?Patient able to give his consent and having previously signed a written informed consent.
- •?Patient affiliated to social security system, if applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •?Any other histological type of lymphoma, Burkitt included.
- •?Any history of treated or non-treated small-B cell lymphoma.
- •?Central nervous system or meningeal involvement by lymphoma.
- •?Contra-indication to any drug contained in the chemotherapy regimens.
- •?Any serious active disease (according to the investigator’s decision).
- •?Poor renal function (creatinin level>150µmol/l), poor hepatic function (total bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
- •?Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l, unless related to bone marrow infiltration.
- •?Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. Patients previously diagnosed with prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason score =7, and a prostate specific antigen (PSA) =10 ng/mL prior to initial therapy, (2) they had definitive curative therapy (ie, prostatectomy or radiotherapy) =2 years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they had no clinical evidence of prostate cancer, and their PSA was undetectable if they underwent prostatectomy or <1 ng/mL if they did not undergo prostatectomy.
- •?Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
- •?Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy
- •?Adult patient under tutelage.
研究者
相似试验
进行中（未招募）
不适用
PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMADiffuse large B Cell lymphomaMedDRA version: 14.1Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017995-26-BEYSARC120
进行中（未招募）
1 期
PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMAEUCTR2009-017995-26-FRGELARC120
已完成
2 期
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 YearsNon Previously Treated CD20+ Diffuse Large B-cell LymphomaNCT01195714The Lymphoma Academic Research Organisation120
进行中（未招募）
1 期
Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma - LNH03-7BCD20+ diffuse large B-cell lymphomaEUCTR2007-001589-34-BEGELA Group150
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of a therapy consisting in combination of two drugs Ofatumumab and Ibrutinib followed by bone marrow transplant taken from donor or consolidation for pretreated high risk patients with Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2015-000684-13-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS80